SCHEMBL3259882

SCHEMBL3259882

O=C(c1ccc(NCc2ccc(Cl)cc2)cc1)N1CCCCC1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.70
MAPT P10636 3/20 0.70
L3MBTL1 Q9Y468 1/20 0.70
RAB9A P51151 3/20 0.61
NPC1 O15118 2/20 0.61
KMT2A Q03164 2/20 0.59
MEN1 O00255 1/20 0.59
LMNA P02545 1/20 0.59
NPSR1 Q6W5P4 1/20 0.59
HDAC1 Q13547 1/20 0.58
GRM5 P41594 4/20 0.55
HSD11B1 P28845 2/20 0.55
HPGD P15428 1/20 0.54
MAPK8 P45983 1/20 0.54
MAPK10 P53779 1/20 0.54
NAMPT P43490 1/20 0.53
HSD17B10 Q99714 1/20 0.52
SLC6A7 Q99884 1/20 0.52
FFAR1 O14842 1/20 0.51
CHRNA7 P36544 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1711101 0.86 SLC6A7 (0.67) ALDH1A1MAPTL3MBTL1RAB9ANPC1
SCHEMBL3237674 0.86 HPGD (0.59) ALDH1A1MAPTL3MBTL1RAB9ANPC1
SCHEMBL3242897 0.85 MAPT (0.54) ALDH1A1MAPTL3MBTL1RAB9ANPC1
SCHEMBL3241843 0.85 NPC1 (0.63) ALDH1A1MAPTL3MBTL1RAB9ANPC1
SCHEMBL26100265 0.84 HPGD (0.55) ALDH1A1MAPTL3MBTL1RAB9ANPC1
SCHEMBL3259879 0.84 MAPT (0.70) ALDH1A1MAPTL3MBTL1RAB9ANPC1
SCHEMBL3230937 0.84 HSD11B1 (0.56) ALDH1A1MAPTL3MBTL1RAB9ANPC1
SCHEMBL3237608 0.83 GRM5 (0.75) ALDH1A1MAPTL3MBTL1RAB9ANPC1
SCHEMBL1711137 0.83 LMNA (0.64) ALDH1A1MAPTL3MBTL1RAB9AKMT2A
SCHEMBL3455787 0.82 HPGD (0.80) ALDH1A1MAPTRAB9ANPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP claimed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US claimed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US claimed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO claimed
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP disclosed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US disclosed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087437-A1 Novel Potassium Channel Blockers KCNB1, KCNJ2, KCNJ11 ALDH1A1 1588/4885MAPT 3110/4885L3MBTL1 1696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.